Quanterix Q3 2026: Revenue Beats, Loss Wider Than Expected

As seen on the 24/7 Wall St. homepage on November 9, 2026.

QTRX Quanterix
Q3 2026
EPS
-$0.46
est -$0.42 -9.5%
Revenue
$35M
est $34M +3.3%

First sequential revenue gain since the commercial overhaul, up 6.3% from Q2, with full-year guidance narrowed to $142 million to $146 million and roughly $70 million in year-end cash with no debt. The loss missed expectations, keeping pressure on a $137 million market cap waiting on FDA clearance of its Alzheimer's blood test.

Continue ReadingShow less

Quanterix posted Q3 2026 revenue of $34.97 million, beating the $33.85 million consensus. More importantly, that result marked a 6.3% sequential gain from Q2, which management called the first step in restoring growth following a commercial reorganization that included new sales leadership. Services revenue, however, slid to $9.36 million from a year earlier, partly because a terminated diagnostics development program weighed on the comparison.

On the bottom line, the company reported a GAAP loss of $0.46 per share, missing the $0.42 consensus. That figure includes acquired intangible amortization and a gain from the change in fair value of contingent liabilities, so the headline loss carries some moving parts. The company disclosed no non-GAAP EPS, meaning investors are working entirely from the GAAP number.

The sequential improvement gave management enough confidence to narrow its full-year 2026 revenue guidance to $142 million to $146 million and reaffirm an adjusted gross margin target of 48% to 50%. The company also projected roughly $70 million in cash with no debt at year-end, a balance-sheet posture that matters given its $137 million market cap. Having essentially no debt removes one source of near-term pressure even as operating losses continue.

Sponsored

The overarching catalyst the market is focused on is FDA clearance of Quanterix's single-site, five-biomarker Alzheimer's blood test, marketed as LucentAD Complete. A 510(k) submission is already with the FDA and active dialogue is underway, while Florida Medicaid began covering the test on November 1, 2026, at a CMS-set price of $897. CEO Everett Cunningham said the company has established what he described as a strong foundation for diagnostics through strategic investments and partnerships, with key milestones in Alzheimer's disease testing still ahead.

Quanterix has fallen short of the bottom-line consensus in six of the past eight quarters, with the one notable exception being Q1 2026, when a reported gain of $0.16 per share came in well ahead of the negative $0.62 estimate. The operational trend is one of persistent losses gradually narrowing, and Q4 will be the next test of whether the commercial overhaul is gaining traction or whether market softness in research tools, particularly in EMEA among pharma and CRO customers, continues to cap the recovery.

Mentioned: QTRX